정신분열병환자에서 Taq I A 도파민 D2 수용체 다형성과 항정신병약물의 치료반응과의 연관
The relationship between Taq I A dopamine D2 receptor polymorphism and therapeutic response to antipsychotics in schizophrenic patients
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Abstract
purpose：In an attempt to predict the interpersonal differences of therapeutic response to antipsychotic drugs on pharmaco-genetic bases, this study was designed to investigate the relationship between the therapeutic response to antipsychotic drugs and Taq I A dopamine D2 receptor polymorphism in schizophrenic patients. Methods：The subjects were 158 patients diagnosed with schizophrenia(DSM-IV). The therapeutic response to antipsychotic drugs was evaluated using the Treatment Response Scale(TRS) retrospectively. Patients were divided into two groups, dopamine receptor antagonist responders, and serotonin-dopamine antagonist responders. The patients’ Taq I A dopamine D2 receptor polymorphism was determined by polymerase chain reaction(PCR) and restriction fragment length polymorphism(RFLP). Results：The dopamine receptor antagonist responders had the A1 allele in significantly higher incidences (χ2(1)=4.875, p=0.027, two-tailed). No significant difference was found among the serotonin-dopamine antagonist responders between those with or without the A1 allele. Conclusions：The patients with the A1 allele responded better to dopamine receptor antagonists than those with no A1 allele. Based on these results, it is suggested that the pharmacological effect of dopamine receptor antagonists can be predicted depending on the presence of the A1 allele in schizophrenic patients.
참고문헌 (34)
- Anonymous. Part A, "Treatment Recommendations forPatients with Schizophrenia.", 161, pp.3~56 (2004)
- Bowers MB, "Plasma catecholamine metabolites and early response tohaloperidol", 45, pp.248~251 (1984)
- Buchsbaum MS, "Effects of clozapine andthiothixene on glucose metabolic rate in schizophrenia", 6, pp.155~163 (1992)
- Kahn RS, "Serotonin function and treatment response toclozapine in schizophrenic patients", 150, pp.1337~1342
- Pickar D, "Neuroleptic-induced decrease inplasma homovanillic acid and antipsychotic activity inschizophrenic patients", 225, pp.954~957 (1984)
- Szymanski S, "Clozapine effects onneuroendocrine response to apomorphine challenge testingin chronic neuroleptic nonresponsive schizophrenia:preliminary findings", 37, pp.52~55 (1995)
- Kawanishi Y, "Pharmacogenomicsand schizophrenia", 410, pp.227~241 (2000)
- Noble EP, "The D2 dopamine receptor gene:a review ofassociation studies in alcoholism and phenotypes", 16, pp.33~45 (1998)
- Sch¨aer M, "Association of shorttermresponse to haloperidol treatment with a polymorphismin the dopamine D(2)receptor gene", 158, pp.802~804 (2001)
- Suzuki A, "The relationship between dopamineD2 receptor polymorphism at the Taq I A locusand therapeutic response to nemonapride,a selectivedopamine antagonist,in schizophrenic patients", 10, pp.335~341 (2000)
- Suzuki A, "Association between TaqI Adopamine D2 receptor polymorphism and therapeuticresponse to bromperidol:a preliminary report", 251, pp.57~59 (2001)
- American Psychiatric Association, "Diagnostic and StatisticalManual of Mental Disorders", pp.285~286 (1994)
- American Medical Association, "AMA Drug Evaluations", American Medical Association
- Csernansky JG, "The treatment response scale:A retrospective methodof assessing response to neuroleptics", 140, pp.1210~1213
- Overall JE, "The brief psychiatric rating scale in psychopharmacology Modernproblems in pharmacopsychiatry" (1974)
- Van Putten T, "Haloperidolplasma levels and clinical response:a therapeuticwindow relationship", 149, pp.500~505 (1992)
- Volavka J, "Haloperidol blood levels and clinicaleffects", 49, pp.354~361 (1992)
- Laird LK, "Prediction of response to antipsychotics", pp.3~13
- Comings DE, "The dopamine D2receptor locus as a modifying gene in neuropsychiatricdisorders", 266, pp.1793~1900 (1991)
- Nothen MM, "Lack of association betweenschizophrenia and alleles of the dopamine D1,D2,D3 and D4 receptor loci", 3, pp.89~94 (1993)
- Lee HS, "Distribution of the TaqIpolymorphism of the dopamine D2 receptor in a Koreanschizophrenic population", 34, pp.1641~1651 (1995)
- Coon H, "Linkage analysis of schizophreniawith five dopamine receptor genes in nine pedigrees", 52, pp.327~334 (1993)
- Sobell JL, "Novel associationapproach for determining the genetic predispositionto schizophrenia:case-control resource and testing of acandidate gene", 48, pp.28~35 (1993)
- Seeman P, "Dopamine receptors. In: Bloom FE, KupferDJ, editors. Psychopharmacology. 4th edn", pp.295~302 (1995)
- Thompson J, "D2 dopamine receptor gene(DRD2) Taq I A polymorphism: reduced dopamine D2receptor binding in the human striatum associated withthe A1 allele.", 7, pp.479~484 (1997)
- Pohjalainen T, "The A1 allele of thehuman D2 dopamine receptor gene predicts low D2receptor availability in healthy volunteers", 3, pp.256~260 (1998)
- Crow TJ,, "Neurotransmitter enzymesand receptors in postmortem brain in schizophrenia evidence that an increase in D2 dopamine receptors isassociated with the Type I Syndrome Transmitter biochemistry of humanbrain tissue", pp.85~96 (1981)
- Scharfetter J, "Dopamine D3 receptorgene polymorphism and response to clozapine in schizophrenicPakastani patients", 10, pp.17~20 (1999)
- Ozdemir V, "Variability in Response toClozapine:Potential Role of Cytochrome P450 1A2 andthe Dopamine D4 Receptor Gene", 4, pp.30~56 (1999)
- Arranz M, "Association between clozapine responseand allelic variation in 5-HT2A receptor gene", 29(346), pp.281~282 (1995)
- Sodhi MS, "Association between clozapine responseand allelic variation in the 5-HT2C receptor gene", 7, pp.169~172 (1995)
- Yu YW, "Serotonin-6 receptor variant(C267T)and clinicalresponse to clozapine", 10, pp.1231~1223 (1999)
- Arranz MJ, "Pharmacogenetic prediction of clozapineresponse", 355, pp.1615~1616 (2000)
- Schumacher J, "Pharmacogenetics of the clozapine response", 356, pp.506~507 (2000)